Magnesium sulphate given before very-preterm birth to protect infant brain: The randomised controlled PREMAG trial

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 114, Issue 3, 2007, Pages 310-318

  Marret, S ^a   Marpeau, L ^a   Zupan Simunek, V ^b   Eurin, D ^a   Leveque C ^a   Hellot, M F ^a   Benichou J ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

Leucomalacia; Mortality; Neuroprotection; Newborn; Periventricular; White matter

Indexed keywords

MAGNESIUM SULFATE; PLACEBO;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; BRAIN INJURY; BRAIN PROTECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FATALITY; FEMALE; FETUS; FLUSHING; GESTATIONAL AGE; HEADACHE; HEART ARREST; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA AND VOMITING; NEWBORN MORTALITY; PLACENTA PREVIA; POSTPARTUM HEMORRHAGE; PREMATURITY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; TENDON REFLEX; TERTIARY HEALTH CARE; TWIN PREGNANCY; WHITE MATTER;

ADULT; CEREBRAL PALSY; FEMALE; HUMANS; INFANT MORTALITY; INFANT, NEWBORN; INFANT, PREMATURE; INFUSIONS, INTRAVENOUS; LEUKOMALACIA, PERIVENTRICULAR; MAGNESIUM SULFATE; OBSTETRIC LABOR, PREMATURE; PREGNANCY; PREGNANCY OUTCOME; TOCOLYTIC AGENTS;

EID: 33847007984     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2006.01162.x     Document Type: Article

References (35)

1. Marlow N. Neurocognitive outcome after very preterm birth. Arch Dis Child Fetal Neonatal Ed 2004;89:F224-8.
2. Livinec F, Ancel PY, Marret S, Arnaud C, Fresson J, Pierrat V, et al. Prenatal risk factors for cerebral palsy in very preterm singletons and twins. Obstet Gynecol 2005;105:1341-7.
3. Marret S, Marpeau L. Grand prematurity, risk of neuropsychic handicaps and neuroprotection. J Gynecol Obstet Biol Reprod (Paris) 2000;29:373-84.
4. Kuban KC, Allred EN, Dammann O, Pagano A, Leviton A, Share J, et al. Topography of cerebral white-matter disease of prematurity studied prospectively in 1607 very-low-birthweight infants. J Child Neurol 2001;16:401-8.
5. Larroque B, Marret S, Ancel PY, Arnaud C, Marpeau L, Supernant K, et al. White matter damage and intraventricular hemorrhage in very preterm infants: the EPIPAGE study. J Pediatr 2003;143:477-83.
6. Nelson KB, Grether JK. Can magnesium sulphate reduce the risk of cerebral palsy in very low birth weight infants? Pediatrics 1995;95:263-9.
7. Hauth JC, Goldenberg RL, Nelson KG, DuBard MB, Peralta MA, Gaudier FL. Reduction of cerebral palsy with maternal MgSO4 treatment in newborns weighing 500-1000 g. Am J Obstet Gynecol 1995;172:419.
8. Schendel DE, Berg CJ, Yeargin-Allsopp M, Boyle CA, Decoufle P. Prenatal magnesium sulphate exposure and the risk of cerebral palsy or mental retardation among very-low-birth-weight children aged 3 to 5 years. JAMA 1996;276:1805-10.
9. FineSmith RB, Roche K, Yellin PB, Walsh KK, Shen C, Zeglis M, et al. Effect of magnesium sulphate on the development of cystic periventricular leukomalacia in preterm infants. Am J Perinatol 1997;14:303-7.
10. Rouse DJ, Hauth JC, Nelson KG, Goldenberg RL. The feasibility of a randomised clinical perinatal trial: maternal magnesium sulphate for the prevention of cerebral palsy. Am J Obstet Gynecol 1996;175:701-5.
11. Canterino JC, Verma UL, Visintainer PF, Figueroa P, Klein SA, Tejani NA. Maternal magnesium sulphate and the development of neonatal periventricular leucomalacia and intraventricular hemorrhage. Obstet Gynecol 1999;93:396-402.
12. O'Shea TM, Klinepeter KI, Dillard RG. Prenatal events and the risk of cerebral palsy in very low birth weight infants. Am J Epidemiol 1998;147:362-9.
13. Crowther CA, Hiller JE, Doyle LW, Haslam RR; for the Australasian Collaborative Trial of Magnesium Sulphate Collaborative Group (ACTOMgSO4). Effect of magnesium sulphate given for neuroprotection before preterm birth: a randomised controlled trial. JAMA 2003;290:2669-76.
14. Zupan V, Gonzales P, Lacaze-Masmonteil T, Boithias C, d'Allest AM, Dehan M, et al. Periventricular leukomalacia: risk factors revisited. Dev Med Child Neurol 1996;38:1061-7.
15. Murphy DJ, Sellers S, MacKenzie IZ, Yudkin PL, Johnson AM. Case-control study of antenatal and intrapartum risk factors for cerebral palsy in very preterm singleton babies. Lancet 1995;346:1449-54.
16. Ancel PY, Marret S, Larroque B, Arnaud C, Zupan-Simunek V, Voyer M, et al. Are small for gestational age and maternal hypertension risk factors for severe intraventricular hemorrhage and cystic periventricular leucomalacia compared with other causes of very preterm birth? Results of the EPIPAGE cohort study. Am J Obstet Gynecol 2005;193:178-84.
17. Reynolds PR, Dale RC, Cowan FM. Neonatal cranial ultrasound interpretation: a clinical audit. Arch Dis Child Fetal Neonatal Ed 2001;84:F92-5.
18. Ment LR, Vohr B, Allan W, Westerveld M, Katz KH, Schneider KC, et al. The etiology and outcome of cerebral ventriculomegaly at term in very low birth weight preterm infants. Pediatrics 1999;104:243-8.
19. Hosmer DW, Lemeshow S. Applied Logistic Regression, 2nd edn. New York, NY: Wiley & Sons, 2000.
20. Mittendorf R, Pryde P, Khoshnood B, Kwang-Sun L. If tocolytic magnesium sulphate is associated with excess total pediatric mortality, what is its impact? Obstet Gynecol 1998;92:308-11.
21. Courtney SE, Durand DJ, Asselin JM, Hudak ML, Aschner JC, Shoemaker CT, et al. High-frequency oscillatory ventilation versus conventional mechanical ventilation for very-low-birth-weight infants. N Engl J Med 2002;347:647-52.
22. Inder TE, Scott J, Mogridge NB, Spencer C, Volpe JJ. Defining the nature of the cerebral abnormalities in the premature infant: a quantitative magnetic resonance imaging study. J Pediatr 2003;143:171-9.
23. Mildvan A. Role of magnesium and other divalent cations in ATP-utilizing enzymes. Magnesium 1987;6:28-33.
24. McIntosh TK, Vink R, Yamakami I, Faden AI. Magnesium protects against neurological deficit after brain injury. Brain Res 1989;482:252-60.
25. McDonald JW, Johnston MV. Magnesium reduces N-methyl-D-aspartate-mediated brain injury in perinatal rats. Neurosci Lett 1990;109:234-8.
26. Thordstein M, Bagenholm R, Thiringer K, Kjellmer I. Scavengers of free oxygen radicals in combination with magnesium ameliorate perinatal hypoxic-ischemic brain damage in the rat. Pediatr Res 1993;34:23-8.
27. Marret S, Gressens P, Gadisseux JF, Evrard P. Prevention by magnesium of excitotoxic neuronal death in the developing brain: an animal model for clinical intervention studies. Dev Med Child Neurol 1995;37:473-84.
28. Wu YW, Colford JM Jr. Chorioamnionitis as a risk factor for cerebral palsy: a meta-analysis. JAMA 2000;284:1417-24.
29. Atkinson MW, Guinn D, Owen J, Hauth JC. Does magnesium sulphate affect the length of labor induction in women with pregnancy-associated hypertension? Am J Obstet Gynecol 1995;173:1219-22.
30. Shogi T, Miyamato A, Ishiguro S, Nishio A. Enhanced release of IL-1 beta and TNF-alpha following endotoxin challenge from rat alveolar macrophages cultured in low-Mg(2+) medium. Magnes Res 2003;16:111-19.
31. Maier JA, Malpuech-Brugere C, Zimowska W, Rayssiguier Y, Mazur A. Low magnesium promotes endothelial cell dysfunction: implications for atherosclerosis, inflammation and thrombosis. Biochem Biophys Acta 2004;1689:6-12.
32. Benichou J, Zupan V, Fernandez H, Marpeau L, Marret S. Tocolytic magnesium sulphate and paediatric mortality. Lancet 1998;351:290-1.
33. Crowther C, Hiller J, Doyle L, Lumley J, Carlin J. Tocolytic magnesium sulphate and paediatric mortality. Lancet 1998;351:291.
34. Leveno KJ. Tocolytic magnesium sulphate and paediatric mortality. Lancet 1998;351:291-2.
35. Grether J, Hirtz D, McNellis D, Nelson K, Rouse DJ. Tocolytic magnesium sulphate and paediatric mortality. Lancet 1998;351:292.